NICE’s final draft guidance states that the one-time treatment will be made available on the NHS in England under a managed access scheme for patients aged 12 years and older who experience recurrent sickle cell crises.
Those eligible for the therapy will also be suitable for a stem cell transplant, but will not have a matched donor…
